Healthcare research firm KLAS reports that healthcare providers remain strongly concerned about interoperability of technology from various vendors and "strongly encourage better coordination among vendors, timely location of patient records and greatly improved parsing...
Despite some evidence on the benefits of value-based payment, few states have passed legislation to support the transition to VBP systems. When use is the main driver of health spending, state legislation is an important lever to...
Reimbursing accountable care organizations for value in a primarily fee-for-service payment environment is creating implementation challenges for Vermont’s innovative All-Payer ACO Model, according to participants.
The FDA has approved expanded indications for three medications for the treatment of patients with cystic fibrosis with specific mutations in the CFTR gene, according to press release from Vertex Pharmaceuticals.
As the first oral drug in this class, relugolix may reduce or eliminate the need for some patients “to visit the clinic for treatments that require administration by a health care provider,” said Richard Pazdur, MD, the director of the FDA’s Oncology Center...
When the Congress finally passed legislation to end surprise billing in December, it settled on a final-offer arbitration process for settling cases when providers and health plans can’t agree on amount to be paid for an...
A machine-learning model using real-world data can help determine which existing medications can improve outcomes in diseases for which they are not prescribed. Drug repurposing can lower the risk associated with safety testing of new...
Subscribe to Genomics Biotechnology & Emerging Medical Technologies Institute e-News | |
*Email: | |
*First Name: | |
*Last Name: | |
*Company: | |
Title: | |
Street Address: | |
City: | |
State / Province: | |
Zip / Postal Code: | |
Country: | |
Are you a member of NAMCP? | Yes No |
![]() | |
Privacy Policy |